Literature DB >> 22677034

The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.

J Blesa1, C Pifl, M A Sánchez-González, C Juri, M A García-Cabezas, R Adánez, E Iglesias, M Collantes, I Peñuelas, J J Sánchez-Hernández, M C Rodríguez-Oroz, C Avendaño, O Hornykiewicz, C Cavada, J A Obeso.   

Abstract

Parkinson's disease (PD) is diagnosed when striatal dopamine (DA) loss exceeds a certain threshold and the cardinal motor features become apparent. The presymptomatic compensatory mechanisms underlying the lack of motor manifestations despite progressive striatal depletion are not well understood. Most animal models of PD involve the induction of a severe dopaminergic deficit in an acute manner, which departs from the typical, chronic evolution of PD in humans. We have used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administered to monkeys via a slow intoxication protocol to produce a more gradual development of nigral lesion. Twelve control and 38 MPTP-intoxicated monkeys were divided into four groups. The latter included monkeys who were always asymptomatic, monkeys who recovered after showing mild parkinsonian signs, and monkeys with stable, moderate and severe parkinsonism. We found a close correlation between cell loss in the substantia nigra pars compacta (SNc) and striatal dopaminergic depletion and the four motor states. There was an overall negative correlation between the degree of parkinsonism (Kurlan scale) and in vivo PET ((18)F-DOPA K(i) and (11)C-DTBZ binding potential), as well as with TH-immunoreactive cell counts in SNc, striatal dopaminergic markers (TH, DAT and VMAT2) and striatal DA concentration. This intoxication protocol permits to establish a critical threshold of SNc cell loss and dopaminergic innervation distinguishing between the asymptomatic and symptomatic parkinsonian stages. Compensatory changes in nigrostriatal dopaminergic activity occurred in the recovered and parkinsonian monkeys when DA depletion was at least 88% of control, and accordingly may be considered too late to explain compensatory mechanisms in the early asymptomatic period. Our findings suggest the need for further exploration of the role of non-striatal mechanisms in PD prior to the development of motor features.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22677034     DOI: 10.1016/j.nbd.2012.05.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  29 in total

Review 1.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

Review 2.  The use of nonhuman primate models to understand processes in Parkinson's disease.

Authors:  Javier Blesa; Inés Trigo-Damas; Natalia López-González Del Rey; José A Obeso
Journal:  J Neural Transm (Vienna)       Date:  2017-03-29       Impact factor: 3.575

3.  MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.

Authors:  Eduard R Mingazov; Gulnara R Khakimova; Elena A Kozina; Alexei E Medvedev; Olga A Buneeva; Ara S Bazyan; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

4.  Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery.

Authors:  Xiangmin Lin; Min Shi; Jeyaraj Gunasingh Masilamoni; Romel Dator; James Movius; Patrick Aro; Yoland Smith; Jing Zhang
Journal:  Biochim Biophys Acta       Date:  2015-01-22

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 6.  Manganese-Induced Parkinsonism Is Not Idiopathic Parkinson's Disease: Environmental and Genetic Evidence.

Authors:  Tomás R Guilarte; Kalynda K Gonzales
Journal:  Toxicol Sci       Date:  2015-08       Impact factor: 4.849

7.  Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([(18)F]AV-133).

Authors:  Yajing Liu; Feng Yue; Rongping Tang; Guoxian Tao; Xiaomei Pan; Lin Zhu; Hank F Kung; Piu Chan
Journal:  Neurosci Bull       Date:  2013-09-05       Impact factor: 5.203

Review 8.  What basal ganglia changes underlie the parkinsonian state? The significance of neuronal oscillatory activity.

Authors:  A Quiroga-Varela; J R Walters; E Brazhnik; C Marin; J A Obeso
Journal:  Neurobiol Dis       Date:  2013-05-30       Impact factor: 5.996

9.  Reduced Midbrain Dopamine Neuron Number in the Adult Non-human Primate Brain after Fetal Radiation Exposure.

Authors:  Lynn D Selemon; Anita Begovic
Journal:  Neuroscience       Date:  2020-07-11       Impact factor: 3.590

10.  1-Methyl-4-Phenylpyridinium-Induced Death of Differentiated SH-SY5Y Neurons Is Potentiated by Cholesterol.

Authors:  Anu Raju; Parasuram Jaisankar; Anupom Borah; Kochupurackal Parameswarannayar Mohanakumar
Journal:  Ann Neurosci       Date:  2017-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.